Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
International Journal of Antimicrobial Agents|October 29, 2000
Out-patient management of febrile neutropeniaJ A TalcottHematology/Oncology Clinics of North America|June 1, 1996
Quality of life in early prostate cancer. Do we know enough to treat?J A TalcottHematology/Oncology Clinics of North America|June 1, 1994
The prostate specific antigen. Its use as a tumor marker for prostate cancerP W Kantoff, J A TalcottOncology (Williston Park, N.Y.)|September 16, 2000
Ambulatory antimicrobial therapy for hematologic malignanciesK V Rolston, J A TalcottMedical Care|September 22, 2001
Symptom indexes to assess outcomes of treatment for early prostate cancerJ A Clark, J A TalcottBiostatistics (Oxford, England)|August 23, 2003
Binary data with two, non-nested sources of clustering: an analysis of physician recommendations for early prostate cancer treatmentR A Betensky, J A Talcott, J C WeeksJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction ruleJ A Talcott, R D Siegel, R Finberg, et al.Archives of Internal Medicine|December 1, 1988
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentationJ A Talcott, R Finberg, R J Mayer, et al.European Journal of Immunology|September 1, 1976
T cell requirements for the expression of the lipopolysaccharide adjuvant effect in vivo: evidence for a T cell-dependent and a T cell-independent mode of actionD B Ness, S Smith, J A Talcott, et al.Pageof 3